CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, analysts at H.C. Wainwright reiterated a ‘Buy’ rating on the stock and raised ...

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

CRISPR Therapeutics (NASDAQ:CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common shares through Jefferies LLC, acting as its sales agent. The sale ...